More than a biomarker, CA19-9 is a therapeutic target of pancreatic cancer

Pancreatic cancer is one of the deadliest cancer because it lacks a reliable method of early detection. Although CA19-9 is commonly used for monitoring the treatment effect of pancreatic cancer, CA19-9 is not useful for early cancer detection because the serum CA19-9 is increased in both pancreatic cancer and pancreatitis (inflammation of pancreas).

In recent Science journal, Engle et al. found that transgenic mice constitutively expressing CA19-9 promotes the development of pancreatitis and pancreatic tumor progression. Moreover, CA19-9-mediated pancreatitis could be reversed by treatment with CA19-9 antibodies. Their findings implicate CA19-9 as a therapeutic target for pancreatitis and pancreatic cancer.

arigo offer quality antibodies to facilitate the research of pancreatic cancer.

CA19-9 detection

Human CA19-9 ELISA Kit (ARG80645)